Kornimate/medical-research-clean huggingface dataset:
müller's muscle as a new proprioceptive organ

Conditions: Eyelid Movement Disorders; Eyelid Ptosis Congenital

Summary: objectives: upper eyelid retraction was believed to be maintained solely by voluntary contraction of the levator palpebrae superioris (lps) and frontalis muscles, together with involuntary contraction of the sympathetically innervated müller's muscle (mm). however, several studies have suggested that the lps also undergoes involuntary contractions, and that a visual stimulus may not be the only trigger for frontalis muscle contractions. recent studies hypothesized that the mm contains proprioceptive neuronal structures, which elicit involuntary lps muscle contraction by the mesencephalic trigeminal nucleus via a continuous stretch reflex. we aim to identify proprioceptive structures in mm by means of histological examinations. methodology: prospective study. collaboration of oculoplastics, ophthalmologists and a neuroanatomy specialist in sheba medical center. 50 fresh mm specimens from patients undergoing müllerectomies will undergo histologic examinations, including immunohistochemical staining and light and electron microscopy. significance: identification of proprioceptive structures in mm will be the first evidence-based proof of a proprioceptive mechanism in the eyelid. this might have a significant impact on future surgical management of eyelid procedures. comprehensive understanding of the mechanisms underlying eyelid function is especially important in the management of children with ptosis who may have coexisting amblyopia.

the investigators' goal is to find proprioceptive neuronal structures in müller's muscle (mm). the investigatorswill recruit 50 mm specimens of patients diagnosed with either unilateral or bilateral ptosis who were referred to undergo a posterior approach surgical correction (mmcr). in this surgical approach, the proximal part of mm is removed between the levator palpebrae superioris muscle and the tarsus of the upper eyelids. the excised tissue is generally not used but simply discarded. for study purposed, the investigators will obtain the patients' consent to save these tissues and carry out histologic examinations of the samples. no change in the surgical procedure or the following management will be needed.

Eligibility criteria:
inclusion criteria: * specimens from patients undergoing müllerectomies exclusion criteria: * small specimens (\<1 cm length and width)

Keywords: eyelid muller
carotid robotic procedure evaluation

Conditions: Carotid Artery Diseases

Summary: this study aims to evaluate the use of r-one in the peripheral vasculature.

this is a prospective, single-arm, monocenter study to evaluate the r-one use in carotid artery stenting procedures. up to 8 patients will be included and followed at 30 days.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. candidate for cas 3. presence of a web-diaphragm lesion at carotid artery ostium, proved by non-invasive imaging (cta or mra) 4. no minimum delay between previous stroke therapy (imt) is required 5. double antiplatelet therapy the day before the procedure and 1 month after the procedure is required 6. the patient provides written informed consent as approved by the applicable ethics committee and is willing to comply with all study requirements including 30 days follow-up. 7. the patient is affiliated with a social security scheme exclusion criteria: 1. target lesion has atherosclerotic or dissection stenosis or occlusion; 2. treatment of in-stent restenosis, or prior stent in the target vessel proximal to the target lesion; 3. cas performed at the end of intracranial mechanical thrombectomy 4. contra-indications of double antiplatelet therapy the day before the procedure and 1 month after the procedure 5. patients under judicial protection, tutorship or curatorship 6. any patient participating in another clinical study valuating a drug or a medical device (except registries for which the primary endpoint has not been evaluated); 7. pregnant and breast-feeding women or intention to become pregnant prior to completion of all follow-up procedures.
multicenter registry of pediatric lupus nephritis in china

Conditions: Lupus Nephritis; Children; Steroid; Immunosuppressive Treatment

Summary: this study is designed to evaluate the efficacy and safety of the current treatment option and outcome of pediatric lupus nephritis patients in china. investigators will perform prospective registration study among at least 35 pediatric nephrology medical centers in china.


Eligibility criteria:
inclusion criteria: diagnosis of lupus nephritis: * diagnosis of sle according to the 1997 update of the 1982 american college of rheumatology revised criteria for classification of systemic lupus erythematosus * either of the following: positive urine protein detected 3 times within a week, or 24-hour urine protein\>150mg, or upc\>0.2mg/mg, or urinary microalbumin above normal range detected 3 times within a week, or microscopic examination erythrocyte\>5 rbc/hp, or renal dysfunction including glomerular and/or tubular dyfunction, or abnormal renal biopsy and the pathological changes are in accordance with lupus nephritis * the pathological diagnosis of kidney conforms to the international society of nephrology and society of renal pathology (isn/rps) standards in 2003 exclusion criteria (either of the following criteria): * complicated with other systemic diseases, including basic diseases with clinical significance * patients with tumors * patients with abnormal glucose metabolism * immunodeficiency patients * patients diagnosed as tuberculosis, or hepatitis b, or hepatitis c within three months before treatment * patients with other connective tissue diseases (such as sjogren's syndrome, mixed connective tissue disease, etc.) * drug-induced lupus, congenital lupus and other secondary lupus * renal histopathology with non-inflammatory necrotizing angiopathy or thrombotic microangiopathy (tma)
transcutaneous electrical acupoint stimulation(teas) for hypotension after spinal anesthesia in parturients

Conditions: Hypotension

Summary: the purpose of this study is to compare the effect of teas on hypotension after spinal anesthesia in patients undergoing cesarean section

patients were randomly assigned to 3 groups, receiving teas , non-acupoint stimulation or no-stimulation after spinal anesthesia respectively. 1.4 ml of bupivacaine mixed with 0.2ml of 50% glucose was given for spinal anesthesia under lateral position. then the patient was switched to supine position and the or table was tilted to the left for 15 degree. the sensory loss level was assessed. the blood pressure and heart rate every 2min were recorded for 30min after spinal anesthesia. the adverse events and use of ephedrine adverse events were recorded as well.

Eligibility criteria:
inclusion criteria: * age\>18yrs * american society of anesthesiologists(asa) status 1-2 * scheduled for elective cesarean under spinal anesthesia * gestational age\>38weeks, singleton pregnancy * informed consented exclusion criteria: * patients with pre-eclampsia or diabetes * patients with hypertension or cardiac dysfunction * disturbance of communication * placental abruption

Keywords: hypotension spinal anesthesia cesarean
evaluation of visiocyt bladder cytology in real life

Conditions: Bladder Cancer

Summary: the study will be offered to all consecutive patients undergoing scheduled cystoscopy at the hospitalisation de jour (hdj) chirurgicale, either as part of a diagnostic approach in the event of suspected bladder tumor (exploration of macroscopic hematuria in particular), or as part of the follow-up of a bladder tumor, according to current recommendations (french ccafu guidelines - update 2020-2022: bladder cancer). once non-opposition has been obtained, clinical data at the time of inclusion will be collected and pseudonymized. urine is collected prior to cystoscopy, on voided urine, for a minimum sufficient quantity of 50 ml. the urine sample is then separated into transport jars, one of which is used for standard cytological analysis, the other for visiocyt cytology (sent to a laboratory platform). in the event of a tumor or suspicious lesion detected at the cystoscopy, a trans-urethral bladder resection (turb) will be scheduled. anatomopathological data from this rtuv will also be collected for comparative analysis to establish the diagnostic performance of the test. the tests performed (apart from the urine sample) are part of the usual care pathway. no additional visits will be specifically requested by the protocol. data from examinations carried out as part of standard pathology management, or suspected pathology, will be used for this research. at the same time, prospective questionnaires on patients' preferences with regard to the various diagnostic examinations for bladder tumours (discrete choice analysis) will be given to patients and completed at the time of cystoscopy.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age, * signed consent to participate, * affiliation with a social security scheme, or beneficiary of such a scheme, * patient to undergo cystoscopy for diagnosis (suspected bladder tumor) or follow-up of bladder tumor exclusion criteria: * patients managed or followed up for a bladder tumor of non-urothelial histology, * renal transplant patients, * patient having received pelvic radiotherapy, * pregnant or potentially pregnant women (of childbearing age, without effective contraception) or nursing mothers, * person in an emergency situation, adult under legal protection (guardianship, curatorship or safeguard of justice), or unable to express consent, * inability to undergo medical follow-up for geographical, social or psychological reasons.
efficacy and safety of brodalumab in adolescents from 12 to 17 years of age with moderate-to-severe plaque psoriasis

Conditions: Psoriasis

Summary: the study will investigate the efficacy and safety compared to placebo and the safety compared to ustekinumab of brodalumab in adolescents with moderate to severe plaque psoriasis. the study will also investigate if brodalumab affects development of vaccination-induced immune responses. the study will run over 62-64 weeks (including screening, treatment, and safety follow-up) for each participant, but with the primary endpoint measured at week 12.


Eligibility criteria:
key inclusion criteria: * subject was diagnosed with chronic plaque psoriasis at least 6 months before randomisation. * subject has a diagnosis of moderate-to-severe plaque psoriasis as defined by pasi ≥12, spga ≥3, and body surface area ≥10% at screening and at baseline. * subject, in whom topical therapy is not adequate, and who is a candidate for systemic therapy. * subject has no evidence of active or latent tuberculosis according to local standard of care. key exclusion criteria: * subject is diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions (e.g., eczema). * subject has been vaccinated with a tetanus toxoid-containing vaccine ≤18 months prior to first dose of investigational medicinal product (imp). for eu and uk: subject has been vaccinated with a tt-containing vaccine within 5 years prior to the first dose of imp. * subject has developed or experienced either guillian-barre syndrome, encephalopathy, arthus-type hypersensitivity, or severe allergic reactions in connection with previous tdap or td vaccine. * subject with chronic or recurrent infections, or active infection, systemically treated within 4 weeks prior to first dose of imp. * subject has a known history of crohn's disease. * subject has any active malignancy or a history of any malignancy within 5 years. * subject has a history of suicidal behaviour and has suicidal ideation with some intent to act or specific plan and intent. * subject has a history of depressive disorder with severe episode(s) within the last 2 years. * subject has received anti-il-12/23p40 for less than 12 months prior to the first dose of imp or has previously no response to anti-il-12/23p40 therapy. * subject has previously received anti-il-17 therapy.
comparing two doses of oral melatonin as premedication in children undergoing surgery

Conditions: Preoperative Anxiety

Summary: preoperative anxiety is a common issue in pediatric anesthesia. children often experience anxiety and uneasiness due to uncertain outcomes. surgery and anesthesia are among the most traumatic experiences for children, often considered anxiety-inducing medical treatments. because they lack control over their environment and circumstances, children undergoing medical procedures typically experience significant unease or anxiety. several studies have reported that 50%-80% of children experience preoperative anxiety. in order to reduce kids anxiety intensity, several measures are utilized. these strategies are either pharmacological, psychological, or behavioural. benzodiazepines are popular drugs that can reduce anxiety in children. the most used one in premedication is midazolam. it is a rapid-acting benzodiazepine that has a short elimination half-life. it has sedative, anxiolytic, hypnotic, and anterograde amnesic effects. midazolam, on the other hand, might have a number of negative consequences, including paradoxical reactions, interactions with opioids, excessive sedation, disorientation, and reduced psychomotor performance. melatonin enhances anti-nociceptive effects, most prominently through the modulation of mt1/mt2 receptors in the brain and spinal cord. in addition, it has been demonstrated that melatonin can interact with additional receptors, including those in the gabaergic system, the nitric oxide (no)arginine route, the n-methyl-d-aspartate (nmda) system, and the dopaminergic system, to produce anti-nociceptive and anti-allodynic effects.


Eligibility criteria:
inclusion criteria: * patients of either sex * age from 4 to 14 years * patients with american society anesthesiologist physical status i and ii * patients undergoing elective surgeries exclusion criteria: * asa more than iii * drug allergy. * gastrointestinal disorders.

Keywords: preoperative anxiety general anesthesia major surgery oral melatonin placebo premedication
comparison of anterior vaginal sacrospinofixation with laparoscopic promontofixation for the treatment of anterior and apical genitourinary prolapse

Conditions: Prolapse Genital

Summary: the investigators anticipate a reduced risk of post-operational de novo stress urinary incontinence following surgery for vaginal sacrospinofixation, associated with reduced costs, comparable functional and anatomical efficacy and no increase in morbidity and rate of dyspareunia with the new treatment


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * patient must be available for 12 month follow-up * patient is ≥50 and \<80 years old * patient has pelvic prolapse stage 2 or above according to international pop-q score, concerning the anterior and apical compartments, justifying surgical treatment * patients not having preoperational stress urinary incontinence or having mild stress urinary incontinence not causing significant functional problems (response \<2 to question 17 of pfdi-20 questionnaire). it is possible that patients with hidden stress urinary incontinence will be recruited exclusion criteria: * the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * the patient is under safeguard of justice or state guardianship * the subject refuses to sign the consent * patient with communication issues preventing comprehension of information and administration of questionnaires * pelvic prolapse not affect anterior and apical compartments, regardless of stage * patient with preoperative dyspareunia (patients with mild sexual discomfort related to prolapse may be included * patient presents with preoperative stress urinary incontinence responsible of significant functional incapacity (response ≥2 to question 17 of pfdi-20 questionnaire). * indication for concomitant suburethral sling * patient with previous history of surgery for stress urinary incontinence * indication of concomitant perineorrhaphy surgery with or without myorrhaphy (in both groups). * contra-indication for general anesthetic * current urinary infection * current vaginal infection
methoxyflurane at moderate high altitudes for pain management

Conditions: Pain

Summary: a randomised, double-blind, cross-over study to assess the analgesic effect of methoxyflurane at moderate high altitudes in a wilderness field setting. phase iv, randomised, double-blind, cross-over clinical trial to evaluate the analgesic effect of methoxyflurane at moderate high altitudes in a wilderness field setting, in 24 healthy volunteers

primary outcome: to assess the analgesic efficacy of inhaled methoxyflurane at moderate high altitudes in a wilderness setting. secondary outcomes: to assess the comparative safety and adverse events with inhaled methoxyflurane at moderate high altitudes in a wilderness setting.

Eligibility criteria:
inclusion criteria: 1. male or female between 18 and 65 years of age (inclusive). 2. able to provide informed consent and comply with study-related procedures exclusion criteria: 1. history of diabetes 2. renal or hepatic disease or impairment (defined as a value exceeding the maximum reference range) 3. chronic or nociplastic pain 4. chronic fatigue syndrome 5. chronic/regular use of analgesic medications 6. personal or familial history of malignant hyperthermia 7. personal or familial history of anaesthesia-induced rhabdomyolysis 8. personal history of anaesthesia volatile-induced hepatitis or drug induced liver injury 9. recent volatile anaesthesia (within 6 months) 10. history of significant altitude-related illness 11. significant underlying medical condition which precludes gentle exercise at moderate high altitude (\<2500 m asl) as determined by the investigators 12. hypersensitivity to penthrox/penthrop®, methoxyflurane or any fluorinated anaesthetic. 13. concurrent treatment with cyp 2a6 or cyp 2e1 enzyme inducers (such as: phenobarbital, rifampicin, alcohol or isoniazid) 14. pregnancy

Keywords: altitude analgesia methoxyflurane wilderness medicine
heterogeneity of tertiary lymphoid structures predicts distinct malignancy and immune microenvironment in prostate cancer: a retrospective cohort study

Conditions: Prostate Cancer

Summary: the aim of this study was to reveal the predictive value of spatial heterogeneity and maturity difference of tertiary lymphoid structure in pathological sections of prostate cancer patients for clinical features and prognosis. it provides a new idea for the selection of prostate cancer immunotherapy population in the future.


Eligibility criteria:
inclusion criteria: 1.patients diagnosed with prostate cancer who underwent radical prostatectomy or prostate puncture exclusion criteria: 1. incomplete medical records, inadequate follow-up information, and confirmed non-prostatic acinar adenocarcinoma.
validation of the french version of the geriatric mental state (gms)

Conditions: Validate the French Version of GMS Package

Summary: a major public health issues of today's aging population is the development of knowledge and expertise in geriatric medicine and psychiatry of the elderly. the depressive disorders and dementia, are among the psychiatric conditions most common in older age. they are the subject of much clinical research, in which brain imaging techniques used to establish correlations anatomo-clinical and radiological-clinical. the prerequisite for the realization of such work locally, is the validation in their french version of clinical assessment tools most commonly used internationally, ensuring reliability, acceptability and comparability of results. among these tools, "geriatric mental schedule (gms) package", is the reference tool for research in psychiatry of the elderly. it is a standardized and structured questionnaire that allows to establish with reliability and reproducibility on the basis of answers to questions, major psychiatric diagnoses in the elderly. it has been validated in several languages (german, spanish, italian, dutch, but also chinese, korean ...), but is still not available in french. hypothesis: validate the the french version of "geriatric mental schedule (gms) package", to establish diagnoses of dementia and depressive disorders.

patients 65 years or more, nearest available to assist with the interview of informal caregivers for the subjects in the "dementia", meets the icd-10 criteria for dementia, and cdr score at 1 to 2, with or without treatment for the subjects in the "depression", icd-10 criteria for major depression, score on the depression scale madrs of 18 or more, with or without treatment for control subjects, level of education based on the number of years of schooling (compulsory education until 16 years, extended school) affiliation with a social security scheme consent signed by the subject and the near non-inclusion criteria subjects with symptoms involving mixed dementia and depression such as not allowing complete icd-10 criteria for dementia or depression.

Eligibility criteria:
inclusion criteria: * nearest available to assist with the interview of informal caregivers for the subjects in the "dementia", meets the icd-10 criteria for dementia, and cdr score at 1 to 2, with or without treatment for the subjects in the "depression", icd-10 criteria for major depression, score on the depression scale madrs of 18 or more, with or without treatment for control subjects, level of education based on the number of years of schooling (compulsory education until 16 years, extended school) exclusion criteria: * subjects with symptoms involving mixed dementia and depression such as not allowing complete icd-10 criteria for dementia or depression.

Keywords: gms-package;dementia;depression
testosterone for fatigue in men with ms

Conditions: Multiple Sclerosis

Summary: fatigue is a major symptom in people with multiple sclerosis (ms), for which treatments are limited. several studies have shown that a large proportion of men with ms have low testosterone levels. we propose a two-site clinical trial using topical testosterone gel as a treatment for ms-related fatigue in men with progressive ms who have low or low-normal testosterone levels.


Eligibility criteria:
inclusion criteria: 1) men with spms or ppms, 2)18-60 years old, 3) edss of 1.0- 6.5, 4) low or low-normal t \ 3.6. exclusion criteria: 1) prostate specific antigen \> 2.5 (\ 3.5 (age \>50yr of age), 2) baseline hematocrit greater than the upper limit of normal for the laboratory used, 3) ekg with ischemic changes, 4) history of myocardial infarction, unstable angina, stroke, transient ischemic attack, or deep vein thrombosis, 5) history of prostate or breast cancer, 6) screening t level \>500ng/dl, 7) diabetes requiring treatment, 8) current drug/alcohol abuse, 9) disease other than ms causing fatigue, such as obstructive sleep apnea or other sleep disorder, or untreated thyroid dysfunction, 10) rrms, 11) beck depression inventory-ii (bdi) score over 20, 12) cognitive dysfunction such that subject cannot perform study tests, 13) inability to undergo mri, 14) current or expected use of amphetamines, or 15) anticipated changes in medical treatments that might affect fatigue scores (e.g., expected changes in spasticity, sleep, or depression medications).

Keywords: testosterone multiple sclerosis fatigue